Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In CNS/Brain Cancer CNS/Brain Cancer for November/December 2020 Dexamethasone may ‘jeopardize’ benefit of immunotherapy in glioblastoma, Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest, Immunotherapy could fill unmet need in leptomeningeal metastases, Molecular features of medulloblastoma may help personalize radiotherapy, More must reads CNS/Brain Cancer for September/October 2020 ‘Tour de force’ study reveals therapeutic targets in 38% of cancer patients, Survey quantifies COVID-19’s impact on oncology, New radiomic model may improve prognostication in meningioma, More must readsCNS/Brain Cancer for July/August 2020 VTE, sepsis risk increased among COVID-19 patients with cancer, Aspirin may accelerate cancer progression in older adults, Intraventricular methotrexate may improve survival for medulloblastoma subtypes, Early data support further study of ivosidenib in mIDH1 glioma, Analysis of early onset cancers suggests need for genetic testing, More must readsCNS/Brain Cancer for May/June 2020 Tumor markers are ‘valuable’ for relapse detection in rare CNS tumors, Incidence of CNS tumors appears lower in Chinese children, Novel penclomedine shows promise for some AYAs with CNS cancers Safety Mechanism, Video coaching may relieve anxiety and distress for long-distance cancer caregivers, More must readsCNS/Brain Cancer for March/April 2020 Cancer prevalence among COVID-19 patients may be higher than previously reported, CNS cancer outcomes worse for black and Hispanic children, Intensive AT/RT regimen sets new efficacy benchmark, CLTX-CAR T cells exhibit preclinical activity and move on to a clinical trial, More must readsPages1 2 3 4 last »
